Johnson & Johnson (JNJ)vsTango Therapeutics Inc (TNGX)
JNJ
Johnson & Johnson
$232.77
-2.48%
HEALTHCARE · Cap: $567.28B
TNGX
Tango Therapeutics Inc
$22.15
-13.38%
HEALTHCARE · Cap: $5.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 168980% more annual revenue ($96.36B vs $56.99M). JNJ leads profitability with a 21.8% profit margin vs -188.1%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
TNGX
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.8%
Fair Value
$136.12
Current Price
$232.77
$96.65 premium
Intrinsic value data unavailable for TNGX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Trading at 8.7x book value
0.0% earnings growth
ROE of -27.4% — below average capital efficiency
Revenue declined 100.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : TNGX
The strongest argument for TNGX centers on Debt/Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : TNGX
The primary concerns for TNGX are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while TNGX is a turnaround play — different risk/reward profiles.
TNGX carries more volatility with a beta of 1.19 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 20/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Tango Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation, specializing in synthetic lethality and targeted therapies. With a robust pipeline of promising drug candidates focused on precision oncology, the company is uniquely positioned to address critical unmet needs in cancer care. Strategic collaborations with top academic institutions bolster its research and development efforts, enhancing its ability to deliver transformative therapeutic solutions. Tango Therapeutics aims to significantly improve patient outcomes and redefine treatment paradigms in oncology, making it a compelling investment opportunity in the biopharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?